Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has granted orphan drug designation to BrainEver's product BREN-02, the recombinant human homeoprotein Engrailed 1, for the treatment of amyotrophic lateral sclerosis.
Product Name : BREN-02
Product Type : Protein
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable